Novartis Voluntary Nationwide Recalls Three Lots of Promacta (eltrombopag, 12.5 mg) Oral Suspension Due to Peanut Contamination

Novartis Voluntary Nationwide Recalls Three Lots of Promacta (eltrombopag, 12.5 mg) Oral Suspension Due to Peanut Contamination

Shots:

  • Novartis recalls three lots of Promacta oral suspension to the consumer level due to the presence of peanut floor contamination occurred at third-party manufacturing facility and is conducted within the knowledge of the US FDA
  • The voluntary recall is done for the lot numbers 8H57901589, 9H57900189 & 9H57900289 with no reported adverse event till date. The Promacta 12.5 mg, 25 mg, 50 mg, 75 mg tablets have no impact of the recall
  • Promacta (eltrombopag, 12.5 mg,) is a TPO receptor agonist and is indicated for the treatment of chronic immune thrombocytopenia, severe aplastic anemia with no prior immunosuppressive therapy in adults & pediatric patients, also indicated for hepatitis C-associated thrombocytopenia in adults only

 Click here to read full press release/ article | Ref: Novartis | Image: Jekseng